Pfizer receives FDA emergency authorisation for oral Covid-19 treatment
The US regulator’s decision is based on the data from the Phase 2/3 EPIC-HR trial, which enrolled non-hospitalised…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
23 Dec 21
The US regulator’s decision is based on the data from the Phase 2/3 EPIC-HR trial, which enrolled non-hospitalised…
22 Dec 21
The sBLA submission was based on positive results from the Phase 3 trial, in which Ultomiris significantly improved…
21 Dec 21
The drug, administered six times per year, showed superior efficacy to daily oral PrEP option, in reducing the…
20 Dec 21
Tezspire is also being developed for other potential indications, including chronic obstructive pulmonary disease, chronic rhinosinusitis, chronic spontaneous…
20 Dec 21
The WHO EUL for Novavax’s Covid-19 vaccine is currently under assessment; will be completed following European Medicines Agency…
17 Dec 21
The committee advice allows the European Union (EU) member states to decide on the supply and use of…
16 Dec 21
Orencia is a selective costimulation modulator that disrupts the continuous cycle of T-cell activation and was approved for…
13 Dec 21
Previously approved by the authorities in the UK, Japan and South Korea, Cibinqo is an oral Janus kinase…
10 Dec 21
Last month, the US regulator has expanded the EUA for a booster dose of the vaccine to include…
09 Dec 21
In the Phase 3 trial, a single dose of Evusheld, administered as two intramuscular injections, showed superior efficacy…